ACAD
35.15
+0.9
+2.63%
AEMD
4.71
-0.05
-1.0483%
APRI
0.42
-0.002
-0.4970%
ARNA
1.615
-0.005
-0.309%
ATEC
0.205
+0.005
+2.500%
CNAT
2.24
0.00
0.00%
CRXM
0.18
-0.001
-0.7735%
CYTX
2.91
-0.05
-1.69%
DXCM
63.64
+0.16
+0.25%
GNMK
6.84
+0.2
+3.01%
HALO
9.6
+0.28
+3.00%
ILMN
142.16
+2.33
+1.67%
INNV
0.26
+0.03
+14.58%
INO
10.908
+0.098
+0.907%
ISCO
2.32
+0.12
+5.45%
ISIS
57.56
0.00
0.00%
LGND
119.25
-0.05
-0.04%
LPTN
0.199
+0.022
+12.5495%
MBVX
0.62
-0.02
-3.12%
MEIP
1.39
+0.01
+0.7319%
MNOV
6.71
+0.11
+1.67%
MRTX
17.15
+0.29
+1.72%
MSTX
0.31
+0.002
+0.6829%
NBIX
48.32
+0.25
+0.52%
NUVA
53.69
+0.47
+0.88%
ONCS
1.61
0.00
0.00%
ONVO
2.636
+0.046
+1.7722%
OREX
0.4
-0.01
-3.52%
OTIC
13.87
+0.36
+2.66%
QDEL
16.46
+0.28
+1.73%
RCPT
231.96
0.00
0.00%
RGLS
5.77
+0.07
+1.23%
RMD
58.15
+0.73
+1.27%
SPHS
0.9
-0.02
-2.2174%
SRNE
6.49
+0.06
+0.93%
TROV
5.35
+0.2
+3.8815%
VICL
0.397
+0.007
+1.795%
VOLC
18
0.00
0.00%
ZGNX
9.74
+0.18
+1.88%
ACAD
35.15
+0.9
+2.63%
AEMD
4.71
-0.05
-1.0483%
APRI
0.42
-0.002
-0.4970%
ARNA
1.615
-0.005
-0.309%
ATEC
0.205
+0.005
+2.500%
CNAT
2.24
0.00
0.00%
CRXM
0.18
-0.001
-0.7735%
CYTX
2.91
-0.05
-1.69%
DXCM
63.64
+0.16
+0.25%
GNMK
6.84
+0.2
+3.01%
HALO
9.6
+0.28
+3.00%
ILMN
142.16
+2.33
+1.67%
INNV
0.26
+0.03
+14.58%
INO
10.908
+0.098
+0.907%
ISCO
2.32
+0.12
+5.45%
ISIS
57.56
0.00
0.00%
LGND
119.25
-0.05
-0.04%
LPTN
0.199
+0.022
+12.5495%
MBVX
0.62
-0.02
-3.12%
MEIP
1.39
+0.01
+0.7319%
MNOV
6.71
+0.11
+1.67%
MRTX
17.15
+0.29
+1.72%
MSTX
0.31
+0.002
+0.6829%
NBIX
48.32
+0.25
+0.52%
NUVA
53.69
+0.47
+0.88%
ONCS
1.61
0.00
0.00%
ONVO
2.636
+0.046
+1.7722%
OREX
0.4
-0.01
-3.52%
OTIC
13.87
+0.36
+2.66%
QDEL
16.46
+0.28
+1.73%
RCPT
231.96
0.00
0.00%
RGLS
5.77
+0.07
+1.23%
RMD
58.15
+0.73
+1.27%
SPHS
0.9
-0.02
-2.2174%
SRNE
6.49
+0.06
+0.93%
TROV
5.35
+0.2
+3.8815%
VICL
0.397
+0.007
+1.795%
VOLC
18
0.00
0.00%
ZGNX
9.74
+0.18
+1.88%
Home » Archive by Category

Syndication

Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering

May 6, 2016 – 2:30 pm

SAN DIEGO and VANCOUVER, British Columbia, May 6, 2016 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that it is raising approximately $5 million at a price of $1.40 per share. Additionally, for each share of common stock purchased, the investor will receive a warrant to purchase one-half of a share of common stock of the Company at a price of $1.40 per full share for a period of five years from closing.

Roth Capital Partners served as sole placement agent. After the placement agent fees and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $4.6 million. The offering is expected to close on May 11, 2016, subject to customary closing conditions.

The Company intends to use the net proceeds from the offering for general corporate purposes and to service its outstanding debt owing under a secured promissory note. 

The shares described above are being offered by Sophiris pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission. A prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Roth Capital Partners, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660, (800) 678-9147 or by accessing the SEC’s website, www.sec.gov.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin is in Phase 3 clinical development for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Topsalysin is also currently in Phase 2 clinical development for the treatment of localized low to intermediate risk prostate cancer. For more information, please visit www.sophirisbio.com.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the proposed public offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including market conditions, risks associated with the cash requirements of our business and other risks detailed from time to time in our filings with the Securities and Exchange Commission, and represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.

Company Contact:

Peter Slover

Chief Financial Officer

(858) 777-1760

Corporate Communications and Investor Relations:

Jason Spark

Michael Moore

Canale Communications

NATIONAL Equicom

Corporate Communications and IR

Investor Relations

(619) 849-6005

(858) 886-7813

jason@canalecomm.com 

mmoore@national.ca

 

 

 

 

SOURCE Sophiris Bio Inc.

Research Associate (Sorrento Valley)

May 6, 2016 – 1:51 pm

Our client, a global leader in the Biotech space, is seeking a qualified Research Manufacturing Associate to join their rapidly expanding team!
Duties:
? Unpacking, inspecting and accessioning saliva samples in a BSL2 environment
? Extract DNA fro […

Zymo Research Highlights DNA Preservation and Purification Technology for Urine Specimen Samples at AUA 2016

May 6, 2016 – 1:30 pm

SAN DIEGO, May 6, 2016 /PRNewswire/ — Zymo Research Corporation will display its Quick-DNA Urine Kit at the American Urological Association’s Annual Meeting, the largest gathering of urologists in the world. The kit, that extracts and isolates total DNA from a large volume of urine (40 ml), will be premiered to the urological community at the company’s booth #5151 at the San Diego Convention Center along with Zymo Research’s Urine Conditioning Buffer (UCB) that preserves DNA/RNA in urine for up to one month at ambient temperature.

Urine samples may need to be stored for several weeks before the laboratory can extract or process DNA from the sample. The UCB from Zymo Research prevents microbial growth and preserves DNA in urine samples for up to one month at ambient temperature without the need for dry ice or refrigeration. Only a small amount of buffer is needed (70 µl) to preserve large amounts of urine (1 ml). UCB is sold with the Quick-DNA Urine Kit but may also be purchased separately. The buffer can be used with any type of collection device, which is beneficial for DNA/RNA tests that use urine specimens for analysis.

The Quick-DNA Urine Kit rapidly isolates cellular and/or cell-free DNA with the capability of recovering DNA fragments from 100 bp to 23 kb. The kit utilizes Zymo Research’s Zymo-Spin column technology that ensures DNA can be used for all sensitive downstream applications such as qPCR, DNA sequencing, arrays, and DNA methylation analysis.

Dr. Yap Ching Chew, Director of Epigenetics Technologies at Zymo Research Corporation, noted, “The ability of the Zymo Quick-DNA Urine Kit to effectively recover urine DNA is significantly helpful for urologists when using urine samples to detect urinary tract-related diseases.”

About Zymo Research Corporation
Zymo Research Corporation is a privately held company based in Irvine, California, USA. Since its inception in 1994 it has been serving the academic and biopharmaceutical scientific communities by providing DNA and RNA purification products. Their goal is to help scientists reduce time in the lab by eliminating steps and making the entire DNA/RNA extraction process simpler and faster. In addition to the nucleic acid purification products, Zymo Research also offers genetic, epigenetic and transcriptome analysis services. Zymo Research provides high quality products that are simple to use yet robust in their performance.

For more information, please visit: www.zymoresearch.com. Follow Zymo Research Corporation on Facebook, LinkedIn, Twitter, and Instagram.

All trademarks are the property of their respective owners. Zymo Research Corporation, the stylized logo, tagline “The Beauty of Science is to Make Things Simple”, Quick-DNA, Zymo-Spin, Urine Conditioning Buffer, and UCB are trademarks of Zymo Research Corporation and are registered with the USPTO.

Photo – http://photos.prnewswire.com/prnh/20160506/364727 
Logo – http://photos.prnewswire.com/prnh/20160506/364743LOGO

 

SOURCE Zymo Research Corp.

Clinical Research Associate 2 (Pacific Beach)

May 6, 2016 – 11:22 am

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Every member of our t […

Staff Accountant (Pacific Beach)

May 6, 2016 – 11:18 am

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Every member of our t […

Manager, Regulatory Affairs (Pacific Beach)

May 6, 2016 – 11:14 am

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Every member of our t […

Medical Monitor (Pacific Beach)

May 6, 2016 – 11:11 am

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Every member of our t […

Research Associate Needed to Join or R&D Biotech Team! Apply Now! (Sorrento Valley)

May 6, 2016 – 10:51 am

Long term temporary opportunity
Mon-fri 8-5 (must be flexible)
Pay: Competitive Pay/DOE
Essential Duties and Responsibilities:
? Responsible for assisting scientific staff in carrying out research assignments involving a variety of laboratory met […

Immunology Research Associate Opening With Growing Company! (Torrey Pines)

May 6, 2016 – 10:37 am

We are seeking a Research Associate to join our Immunology Lab. Our company is expanding rapidly and we are looking to bring in more talent.
Top Skills:
Flow cytometry, ELISA, Cell culture, FACS, Immunology, Cancer biology
Job Description:
– The […

The Heart Rhythm Society and Boehringer Ingelheim Pharmaceuticals, Inc. award $500,000 in grants to support quality improvement innovation in atrial fibrillation and stroke prevention

May 6, 2016 – 10:00 am

Panel at Heart Rhythm 2016 in San Francisco selects Mark H. Eckman, MD, University of Cincinnati, and Steven A. Lubitz, MD, MPH, Massachusetts General Hospital, for research aimed at improving patient outcomes

SAN FRANCISCO, May 6, 2016 /PRNewswire/ — The Heart Rhythm Society (HRS), in partnership with Boehringer Ingelheim Pharmaceuticals, Inc., announced today that Mark H. Eckman, MD, University of Cincinnati, Cincinnati, and Steven A. Lubitz, MD, MPH, Massachusetts General Hospital, Boston, were awarded the Atrial Fibrillation (AFib) Quality Improvement (QI) Innovation Grant. The grant support will help innovation and advancement in atrial fibrillation and stroke prevention through research aimed at addressing National QI priorities. Dr. Eckman won for his proposal on Shared Decision-Making Tool for Thromboprophylaxis in Atrial Fibrillation and Dr. Lubitz won for his proposal on Automated Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation. They presented to an expert panel during Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions.

Through this effort, Drs. Eckman and Lubitz will collectively receive $500,000 in grants based on the submitted proposals that outline how they will affect the behaviors and performance of patients, providers and/or systems that, when combined with existing standards and practical approaches to care, may enhance patient outcomes. For details on the winners and their proposals, visit www.hrsonline.org/AFibGrant.

“The applications were very innovative and the level of quality was truly impressive. It was inspiring to see such novel ideas and approaches that have the ability to advance the electrophysiology field,” said John Day, MD, FHRS, president of the Heart Rhythm Society. “At next year’s annual meeting, we will welcome back Drs. Eckman and Lubitz to share the outcomes of their grant awards and how they have used the grants to help evolve the ways we work to prevent atrial fibrillation and stroke and, ultimately, improve overall patient care.”

HRS members served as the decision-making panelists. The initial review of applications took place April 19-26, 2016. Thirty-five applications were received and six finalists presented their proposals to the expert panel from 4:30-6:30 p.m. PDT on May 5 in San Francisco during Heart Rhythm 2016. Drs. Eckman and Lubitz will present their outcomes at Heart Rhythm 2017, taking place in Chicago in May 2017.

“Collaborating with the scientific community is a priority for us in improving patient outcomes,” said Azhar Ahmad, executive director, Clinical Development & Medical Affairs, Cardiovascular, Boehringer Ingelheim Pharmaceuticals, Inc. “We welcome the opportunity to support these researchers in advancing our understanding of atrial fibrillation and stroke prevention.” 

About the Heart Rhythm Society

The Heart Rhythm Society is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. Incorporated in 1979 and based in Washington, DC, it has a membership of more than 5,800 heart rhythm professionals in more than 72 countries around the world.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 146 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and families. Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit our Corporate Social Responsibility Report.

In 2014, Boehringer Ingelheim achieved net sales of about $16.96 billion dollars (13.3 billion euros). R&D expenditure corresponds to 19.9 percent of its net sales.

For more information, please visit www.us.boehringer-ingelheim.com, or follow us on Twitter @BoehringerUS.  

Media Contact: Allison Kassel 
(904) 728-2145 
akassel@brgcommunications.com

Lauren Murphy 
(203) 448-1982 
Lauren.murphy@boehringer-ingelheim.com

SOURCE Heart Rhythm Society